Result of AGM

Result of AGM

8 December, 2015. At the annual general meeting of C4X Discovery Holdings plc, a leader in rational drug discovery and design, held earlier today, all resolutions put to shareholders were duly passed. 

--ENDS--

For further information please contact:

C4X Discovery Holdings plc

Clive Dix Executive Chairman 07801 865803

Zeus Capital

Dan Bate 0161 831 1512

Dominic Wilson/Phil Walker 0203 829 5000

FTI Consulting

Matthew Cole 020 3727 1000

About C4XD

C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for rational drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com